Home > Boards > US Listed > Biotechs > Stemline Therapeutics (STML)

Now that the stock is in the toilet

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Lazarus Member Profile
Member Level 
Followed By 91
Posts 4,335
Boards Moderated 1
Alias Born 04/26/01
160x600 placeholder
Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp) Preclinical Data in Systemic Sclerosis, an Autoimmune ... GlobeNewswire Inc. - 6/17/2019 7:30:00 AM
Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp) Clinical Presentations at EHA Congress June 13-15 GlobeNewswire Inc. - 6/13/2019 7:30:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 6/11/2019 5:03:08 PM
Notice of Exempt Solicitation. Definitive Material. (px14a6g) Edgar (US Regulatory) - 6/11/2019 3:44:59 PM
Stemline Therapeutics Announces ASCO Presentation of ELZONRIS Phase 2 Clinical Data in CMML and MF; Provides Next Steps for C... GlobeNewswire Inc. - 6/3/2019 7:30:00 AM
Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at Upcoming EHA Annual Congress GlobeNewswire Inc. - 5/20/2019 7:00:00 AM
Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at the Upcoming ASCO Annual Meeting GlobeNewswire Inc. - 5/16/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/10/2019 4:17:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/10/2019 7:31:17 AM
Stemline Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire Inc. - 5/10/2019 6:30:00 AM
Stemline Therapeutics to Host Conference Call on First Quarter 2019 Financial Results on May 10, 2019 GlobeNewswire Inc. - 5/8/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 5/2/2019 6:03:32 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/30/2019 5:22:44 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/30/2019 5:20:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/29/2019 8:33:42 AM
Stemline Therapeutics Announces New England Journal of Medicine Publication of ELZONRIS (tagraxofusp) Pivotal Study Results GlobeNewswire Inc. - 4/25/2019 7:00:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 4/19/2019 5:02:16 PM
Stemline Therapeutics to Participate in Panel on Myeloid Tumors at the 31st Annual ROTH Conference GlobeNewswire Inc. - 3/18/2019 7:00:00 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 3/15/2019 5:10:18 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/15/2019 4:21:11 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/15/2019 4:11:11 PM
Stemline Therapeutics Reports Fourth Quarter 2018 Financial Results GlobeNewswire Inc. - 3/15/2019 4:01:00 PM
Stemline Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference GlobeNewswire Inc. - 3/6/2019 7:30:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/22/2019 4:40:14 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/14/2019 10:19:52 AM
Lazarus Member Level  Friday, 12/21/18 11:08:47 AM
Re: cashcow3 post# 38
Post # of 51 
Now that the stock is in the toilet and the company finally gets an FDA approval its CRICKETS on the board. Too funny. I'm in at $8.07

U.S. FDA approves Stemline Therapeutics' rare blood disease treatment

Dec 21 (Reuters) - The U.S. Food and Drug Administration on Friday approved Stemline Therapeutics Inc's Elzonris for the treatment of a rare blood disease in adults and children aged two years and above.

This is the first approved treatment for the condition, blastic plasmacytoid dendritic cell neoplasm (BPDCN), Richard Pazdur, director of the FDA's Oncology Center of Excellence, said.

"The standard of care has been intensive chemotherapy, followed by bone marrow transplantation. Many patients with BPDCN are unable to tolerate this intensive therapy, so there is an urgent need for alternative treatment options."

BPDCN is an aggressive and rare disease of the bone marrow and blood that can affect multiple organs, including the lymph nodes and the skin, the FDA said.

The condition is more common in men than women, and in patients who are 60 years and above.

The labeling for Elzonris contains a boxed warning, FDA's harshest, flagging increased risk of capillary leak syndrome, which may be life-threatening or fatal to patients in treatment.

Stemline Therapeutics shares fell as much as 7.8 percent to $8 in early trading.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist